This brand name is authorized in United States. It is also authorized in Lithuania.
The drug HYMPAVZI contains one active pharmaceutical ingredient (API):
1
|
UNII
0UB3OA67O7 - MARSTACIMAB
|
|
Marstacimab is a human monoclonal IgG1 antibody directed against the Kunitz domain 2 (K2) of tissue factor pathway inhibitor (TFPI), the primary inhibitor of the extrinsic coagulation cascade. TFPI initially binds to and inhibits the factor Xa active site via its second Kunitz inhibitor domain (K2). The action of marstacimab to neutralise the inhibitory activity of TFPI may serve to enhance the extrinsic pathway and bypass deficiencies in the intrinsic pathway of coagulation by increasing free factor Xa available to increase thrombin generation and promote haemostasis. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| HYMPAVZI Solution for injection | MPI, EU: SmPC | European Medicines Agency (EU) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| LT | Valstybinė vaistų kontrolės tarnyba | 1101989, 1101990 |
| US | FDA, National Drug Code | 0069-1510, 0069-2151 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.